Gilead EVP exercises 6,002 RSUs into common stock

Q: What did GILD executive Keeley M Cain Wettan report on this Form 4?

Keeley M Cain Wettan reported the exercise of 6,002 restricted stock units, receiving 6,002 common shares, with an additional 2,908 shares delivered or withheld to cover exercise price or tax liability at $133.06 per share.

Q: How many GILD restricted stock units were exercised in this filing?

The filing shows that 6,002 restricted stock units were exercised, each unit converting into one share of Gilead Sciences common stock. These units are subject to a three-year vesting schedule with 33.33% vesting on each yearly anniversary of the grant date.

Q: What price is associated with the GILD shares withheld for tax or exercise costs?

The Form 4 reports that 2,908 common shares were delivered or withheld at a price of $133.06 per share as payment of the exercise price or tax liability related to the restricted stock unit conversion.

Q: Was this GILD Form 4 transaction a market sale or purchase?

The reported activity reflects a derivative exercise of restricted stock units and a related share delivery or withholding for exercise price or tax liability, rather than an open-market purchase or sale. The Form 4 does not report any code “P” purchase or “S” sale transactions.

Gilead Sciences, Inc. executive Keeley M Cain Wettan, EVP Gen Counsel, Legal & Comp, reported a derivative exercise on restricted stock units.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Gilead Sciences, Inc. executive Keeley M Cain Wettan, EVP Gen Counsel, Legal & Comp, reported a derivative exercise on restricted stock units. On 2026-08-10, 6,002 restricted stock units converted into 6,002 shares of common stock, and 2,908 common shares at $133.06 per share were delivered or withheld for payment of exercise price or tax liability. Following the transaction, the reporting person held 13,995 restricted stock units directly.

Insider Trade Summary

6,002 shares exercised/converted

Exercise 3 txns

Insider Cain Wettan Keeley M

Role EVP Gen Counsel, Legal & Comp

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit ^{F1, F2}	6,002	--	--
Exercise	Common Stock ^F1	6,002	--	--
Exercise Price or Tax Liability	Common Stock	2,908	$133.06	$387K

Holdings After Transaction: Restricted Stock Unit — 13,995 contracts (Direct); Common Stock — 8,454 shares (Direct)

Footnotes (2)

F1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2. The restricted stock units have a three-year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested.

Key Figures

RSUs Exercised: 6,002 restricted stock units Common Shares Received: 6,002 shares Shares Delivered/Withheld: 2,908 shares at $133.06 per share +1 more

4 metrics

RSUs Exercised 6,002 restricted stock units Restricted stock units converted into common stock on 2026-08-10

Common Shares Received 6,002 shares Common stock acquired upon RSU conversion on 2026-08-10

Shares Delivered/Withheld 2,908 shares at $133.06 per share Payment of exercise price or tax liability related to RSU exercise

RSUs Held After Transaction 13,995 restricted stock units Direct RSU holdings following the reported transactions

Key Terms

Restricted Stock Unit, three-year vesting schedule, Payment of exercise price or tax liability

3 terms

Restricted Stock Unit financial

"Each restricted stock unit represents the contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

three-year vesting schedule financial

"The restricted stock units have a three-year vesting schedule. 33.33% vest"

Payment of exercise price or tax liability financial

"Payment of exercise price or tax liability by delivering or withholding securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GILD executive Keeley M Cain Wettan report on this Form 4?

Keeley M Cain Wettan reported the exercise of 6,002 restricted stock units, receiving 6,002 common shares, with an additional 2,908 shares delivered or withheld to cover exercise price or tax liability at $133.06 per share.

How many GILD restricted stock units were exercised in this filing?

The filing shows that 6,002 restricted stock units were exercised, each unit converting into one share of Gilead Sciences common stock. These units are subject to a three-year vesting schedule with 33.33% vesting on each yearly anniversary of the grant date.

What price is associated with the GILD shares withheld for tax or exercise costs?

The Form 4 reports that 2,908 common shares were delivered or withheld at a price of $133.06 per share as payment of the exercise price or tax liability related to the restricted stock unit conversion.

How many GILD restricted stock units does the reporting person hold after this transaction?

After the reported transactions, the reporting person directly holds 13,995 restricted stock units. Each unit represents the contingent right to receive one share of Gilead Sciences common stock, subject to the applicable vesting schedule described in the footnotes.

Was this GILD Form 4 transaction a market sale or purchase?

The reported activity reflects a derivative exercise of restricted stock units and a related share delivery or withholding for exercise price or tax liability, rather than an open-market purchase or sale. The Form 4 does not report any code “P” purchase or “S” sale transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/11/2026 - 04:51 PM Accepted by SEC EDGAR 08/11/2026 - 04:51 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cain Wettan Keeley M

(Last)

(First)

(Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP Gen Counsel, Legal & Comp

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/10/2026		M		6,002	A	⁽¹⁾	11,362	D
Common Stock	08/10/2026		F		2,908	D	$133.06	8,454	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽¹⁾	08/10/2026		M			6,002	⁽²⁾	⁽²⁾	Common Stock	6,002	⁽¹⁾	13,995	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. The restricted stock units have a three-year vesting schedule. 33.33% vest on each yearly anniversary of the date of grant until fully vested.

Remarks:

	/s/ Amy Kim by Power of Attorney for Keeley M. Cain Wettan	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR